ARTV — Artiva Biotherapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1817241 ·
Last close
$3.86
Market Cap
$190.81M
52W High
$14.53
52W Low
$2.96
ADV30
1,112,928
Next earnings
2026-11-12
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -31,954,000 -28,822,000 342,975,000 61,234,000 22,259,000
Jun 2026 0 — -26,890,000 -25,005,000 368,633,000 301,454,000 21,131,000
Mar 2026 0 — -24,430,000 -23,516,000 105,955,000 20,955,000 18,108,000
Dec 2025 0 — -21,932,000 -20,772,000 130,940,000 26,701,000 20,970,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-84,478,000
Investing CF
$-162,763,000
Financing CF
$283,010,000
CapEx
$-2,123,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.02
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-407,892,000
Inventory
—
Receivables
$21,000
ST Investments
$257,867,000
EBIT TTM
$-105,206,000
Pretax Income TTM
$-98,115,000
Interest Exp TTM
—
Analysts
4

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -89,810,000 -83,865,000 130,940,000 20,970,000 109,970,000 -76,751,000
Dec 2024 251,000 -67,282,000 -58,179,000 209,581,000 22,940,000 186,641,000 -55,032,000
Dec 2023 33,492,000 -30,671,000 -32,766,000 105,114,000 267,129,000 -162,015,000 -47,430,000
Dec 2022 4,931,000 -59,829,000 -60,976,000 133,054,000 273,750,000 -140,696,000 -50,829,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-90,821,000
OpCashFlow TTM
—
Assets (Latest)
$368,633,000
Forward EPS
$-1.87

Max Pain — expiry 2026-12-18

max pain strike: $5.00 · spot: $3.77 · call oi: 6,595 · put oi: 24
Expected Move to 2026-12-18: ±$1.22 (32.36%) — implied range $2.55 – $4.99 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CGEN COMPUGEN LTD $191.34M $2.02 —
IKT Inhibikase Therapeutics, Inc. $193.57M $1.38 —
DTIL PRECISION BIOSCIENCES INC $196.95M $7.05 —
PALI PALISADE BIO, INC. $181.07M $1.01 —
LCTX Lineage Cell Therapeutics, Inc. $206.36M $0.82 —

News headlines (Yahoo Finance, 1h cache)

Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation
2026-10-27 17:58 · Yahoo
Why Is Artiva Biotherapeutics Discontinuing AlloNK Development and Cutting 94% of Its Workforce?
2026-10-27 16:22 · Yahoo
Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
2026-10-27 15:44 · Yahoo
Artiva Scraps Development Of Lead Drug Candidate After Patient Deaths — ARTV Stock Heads For Worst Session In Over 18 Months
2026-10-27 14:08 · Yahoo
Artiva Biotherapeutics stock tumbles after halting drug trial
2026-10-27 12:40 · Yahoo
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
2026-10-27 11:30 · Yahoo
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
2026-10-01 11:30 · Yahoo
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
2026-09-23 11:30 · Yahoo
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
2026-09-17 12:00 · Yahoo
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
2026-09-08 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.